Meeting
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
Presenter
Qin Xu
Fujian Cancer Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
ChiCTR1900023015
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5524)
DOI
10.1200/JCO.2021.39.15_suppl.5524
Abstract #
5524
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.
Speaker: Angela Green, MD, MSc
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.
Speaker: Jihong Liu
Videos & Slides
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
Speaker: Huaying Wang, M.D., Ph.D
Videos & Slides
2021 ASCO Annual Meeting
AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
Speaker: Lingying Wu, MD, PhD